Benzo[d]isoxazol-3-ol DAAO inhibitors
US7166725B2 · kind B2 · utility
32Cited by
6References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 28, 2004 |
| Grant date | Jan 23, 2007 |
| Priority date | — |
| Expiry date | May 26, 2025 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods for increasing D-Serine concentration and reducing concentration of the toxic products of D-Serine oxidation, for enhancing learning, memory and/or cognition, or for treating schizophrenia, Alzheimer's disease, ataxia, or neuropathic pain, or preventing loss in neuronal function characteristic of neurodegenerative diseases involve administering to a subject in need of treatment a therapeutic amount of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof:wherein
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.